VERASTEM INC (VSTM)       0.664  -0.02 (-3.09%)

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.

Company Info

VERASTEM INC

117 Kendrick St Ste 500

Cambridge MASSACHUSETTS 02494

P: 16172529300.0

CEO: Brian M. Stuglik

Employees: 48

Website: http://www.verastem.com/